f-star raises EUR15m in new financing led by SR One
f-star GmbH, a biopharmaceutical company developing a new generation of antibody based products using its Modular Antibody Technology platform, has closed a EUR15 million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas Venture, Aescap Venture, Novo Ventures,



